The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?